{"schema_version":"secwatch.filing_event.v1","accession":"0001628908-23-000061","form_type":"8-K","ticker":"EVH","cik":"0001628908","company_name":"Evolent Health, Inc.","filed_at":"2023-05-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.733978+00:00","generated_at":"2026-06-16T01:08:09.268125+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Evolent Health Q1 rev. $427.7M (+44%), adj. EBITDA $50.5M; names new COO","bullets":["Revenue $427.7M (+44% YoY); net loss $26.3M; Adj. EBITDA $50.5M (11.8% margin).","Total Lives on Platform 65.6M, up from 17.9M YoY; average unique members 41.3M.","Expanded oncology solution with Centene; national payer agreement with AMSURG for surgical management.","COO Steve Tutewohl departing July 3; Emily Rafferty appointed COO effective same date.","CEO Seth Blackley expressed confidence in 2023 outlook and 2024 EBITDA run-rate target."],"urls":{"canonical":"https://secwatch.observer/filing/0001628908-23-000061","json":"https://secwatch.observer/filing/0001628908-23-000061.json","markdown":"https://secwatch.observer/filing/0001628908-23-000061.md","text":"https://secwatch.observer/filing/0001628908-23-000061.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1628908/000162890823000061/0001628908-23-000061-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1628908/000162890823000061/evh-20230503.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T01:08:09.268125+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"91b3d64fb2ba40ba79d32064be9804ee7d18b8f4","claim":"Evolent Health, Inc. reported the quarter ended March 31, 2023 results: revenue $427.7 million, net income Net loss attributable to common shareholders of Evolent Health, Inc. of $26.3 million.","evidence_excerpt":"to payers and providers, today announced financial results for the quarter ended March 31, 2023. Highlights from the first quarter 2023 announcement include: • Revenue of $427.7 million, an increase of $130.6 million, or 44.0%, from the three months ended March 31, 2022. • Net loss attributable to common shareholders of Evolent Health, Inc. of $26.3 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1628908/000162890823000061/0001628908-23-000061-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Revenue","value":"$427.7 million"},{"label":"Net income","value":"Net loss attributable to common shareholders of Evolent Health, Inc. of $26.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"29d17e5429","claim":"Steve Tutewohl departed as Chief Operating Officer at Evolent Health, Inc..","evidence_excerpt":"In connection with organizational restructuring, the Company is announcing the departure of Steve Tutewohl, Chief Operating Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1628908/000162890823000061/0001628908-23-000061-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"departure"},{"label":"Role","value":"Chief Operating Officer"}],"fact_type":"executive_change"},{"claim_id":"68c6de3283","claim":"Emily Rafferty was appointed as Chief Operating Officer at Evolent Health, Inc..","evidence_excerpt":"On May 3, 2023, the Company’s Board of Directors appointed Emily Rafferty to serve as the Company’s Chief Operating Officer, effective July 3, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1628908/000162890823000061/0001628908-23-000061-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Operating Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}